, Merck, Pfizer. Omid Hamid (OH): Consulting/Advi‐ sory Board: Aduro, Akeso, Amgen, Beigene, Bioatla, BMS, Roche Genentech, GSK, Immunocore, Idera, Incyte, Janssen, Merck, Nextcure, Novartis, Pfizer, Sanofi ... resistance, lending insights into more advanced melanoma and other diseases. The neoadjuvant setting also offers the opportunity to prioritise drugs for further development. Omid Hamid: in favour of adjuvant
with ethical standards Conflict of interest Omid Hamid has been an investigator, consultant, and speaker for Amgen Inc. Brianna Hoffner has been a consultant to Merck, Novartis, Genentech, and Amgen Inc
compared to changing therapy at PD. Omid Hamid: in favor of switching during stable disease Although it may be true that the majority of patients with CR are those with a low tumor burden, these patients ... before immunotherapy Full size image Omid Hamid: No The evidence in favour of stopping treatment while on response is weak. Landmark analysis reveals that some patients exhibit sustained durable
likelihood of a future role of anti-CTLA-4 in combination with anti-PD-1 therapy. Omid Hamid: no Ipilimumab is a very potent and effective drug. If we are going to relegate it to being a watered down ... MSD. Omid Hamid (OH): Consultant/Advisory Role: Bristol-Meyers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Amgen, Array, Merck Serono. Expert Testimony—Genentech. Other—Bristol-Meyers
). However, ultimately the decision about whether to treat with targeted therapy or immunotherapy first requires a randomised controlled trial. In favour of immunotherapy first: Omid Hamid Immunotherapy ... Funding: Bristol-Meyers Squibb, Roche-Genentech, Array. Corrado Caracò (CC) declares he has no conflict of interest to report. Jeffrey Gershenwald (JG): advisory board for Merck. Omid Hamid (OH
simple correlation and provide in vivo proof-of-concept for different combination therapy approaches. Omid Hamid: in favour of human models In melanoma, approximately 80% durable complete responses have ... Alberto Mantovani in:PubMed • Google Scholar Search for Paul Nathan in:PubMed • Google Scholar Search for Omid Hamid in:PubMed • Google Scholar Search for Katerina Politi in:PubMed • Google Scholar
Epacadostat is a potent inhibitor of the immunosuppressive indoleamine 2,3-dioxygenase 1 (IDO1) enzyme. We present phase 1 results from a phase 1/2 clinical study of epacadostat in combination with ipilimumab, an anti-cytotoxic T-lymphocyte-associated protein 4 antibody, in advanced melanoma (NCT01604889). Only the phase 1, open-label portion of the study was conducted, per the...
BackgroundMucosal melanoma is an aggressive melanoma with poor prognosis. We assessed efficacy of pembrolizumab in patients with advanced mucosal melanoma in KEYNOTE-001 (NCT01295827), −002 (NCT01704287), and −006 (NCT01866319).MethodsPatients received pembrolizumab 2 mg/kg every 3 weeks (Q3W) or 10 mg/kg Q2W or Q3W. Response was assessed by independent central review per RECIST...
, Georgina V. Long , F. Stephen Hodi, Jennifer Tsoi, Catherine S. Grasso, Bijoyesh Mookerjee, Qing Zhao, Razi Ghori, Blanca Homet Moreno, Nageatte Ibrahim and Omid Hamid In the version of this article
Following publication of the original article [1], it was reported that the legend for Fig. 1 was incomplete. The complete figure legend is:
NantKwest. Omid Hamid reports consultancy for Amgen, Novartis, Roche, Bristol-Myers Squibb, and Merck; speakers bureau for Bristol-Myers Squibb, Genentech, Novartis, and Amgen; and research funding from
Purpose The therapeutic index of proteasome inhibitors may be improved through selective inhibition of a sub-component of the ubiquitin-proteasome system, such as the NEDD8-conjugation pathway. This multicenter, phase I, dose-escalation study assessed safety and the maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and antitumor activity of pevonedistat, an...
Claus Garbe in:PubMed • Google Scholar Search for Omid Hamid in:PubMed • Google Scholar Search for Roger S. Lo in:PubMed • Google Scholar Search for Jason J. Luke in:PubMed • Google Scholar Search for ... , MerckSerono, MSD, Novartis, Philogen, Roche. Omid Hamid (OH): Consultant/Advisory Role: Bristol-Meyers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Amgen, Array, Merck Serono. Expert Testimony
Background:Anti-PD-1 therapy has shown significant clinical activity in advanced melanoma. We developed and validated a clinical prediction scale for response to anti- PD-1 monotherapy.Methods:A total of 315 patients with advanced melanoma treated with pembrolizumab (2 or 10 mg kg−1 Q2W or Q3W) or nivolumab (3 mg kg−1 Q2W) at four cancer centres between 2011 to 2013 served as the...
Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with poor survival outcomes in patients with distant metastatic disease (mMCC). In an initial analysis from JAVELIN Merkel 200, a phase 2, prospective, open-label, single-arm trial in mMCC, avelumab—a human anti–programmed death-ligand 1 (PD-L1) monoclonal antibody—showed promising efficacy and a safety...
